VIP

VIP (Vasoactive Intestinal Peptide) is a 28-amino acid neuropeptide belonging to the glucagon/secretin superfamily that was first isolated from porcine intestinal tissue and has since been identified as a widely distributed signaling molecule in both the central and peripheral nervous systems. In research applications, VIP serves as a pharmacological tool for investigating the VPAC1 and VPAC2 receptor signaling pathways, both of which are class B G protein-coupled receptors that signal predominantly through Gs-mediated cAMP production in target cells.

VIP has been studied in an extraordinary diversity of cellular contexts, including neuronal survival and differentiation, immune cell modulation, smooth muscle physiology, exocrine secretion mechanisms, and circadian rhythm regulation in suprachiasmatic nucleus (SCN) neuronal cultures. In immunological research, VIP has been demonstrated to modulate macrophage activation, inhibit pro-inflammatory cytokine production (including TNF-alpha, IL-6, and IL-12), and promote regulatory T cell differentiation in vitro — findings that have established it as a key research tool in the field of neuroimmunology and neuropeptide-mediated immune regulation.

Coffee & Pepper Peptides provides VIP as a research-grade lyophilized peptide with full quality documentation including certificates of analysis. This product is intended for laboratory research only and is not approved for human or animal use.

FDA DISCLAIMER

The information provided on this website has not been evaluated by the U.S. Food and Drug Administration (FDA). None of the statements herein, nor any of the products offered, are intended to diagnose, treat, cure, or prevent any medical condition.

All products are supplied strictly as laboratory research reagents and are not for human consumption. We do not provide products to patients and do not make any claims regarding medical use.

Coffee & Pepper Peptides operates solely as a chemical supplier. It is not a compounding pharmacy and does not operate as a compounding facility under Section 503A of the Federal Food, Drug, and Cosmetic Act.